ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)
$8.67 -1.09 (-11.168%)
Analysed ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) News Sources
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
12-01-2026
biopharmadive.com
Top Midday Decliners
13-01-2026
yahoo.com
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
03-03-2026
biopharmadive.com
Atara Biotherapeutics: Q4 Earnings Snapshot
16-03-2026
yahoo.com
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
01-04-2026
yahoo.com
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
03-04-2026
yahoo.com
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
07-05-2026
advfn.com
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
21-05-2026
yahoo.com
Atara Biotherapeutics Announces Changes to Its Board of Directors
12-06-2026
yahoo.com
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
17-06-2026
yahoo.com
What is the current price of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)?
The current price of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) is $8.67.
ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) since the previous trading day is $-1.09.
ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) since the previous trading day is -11.168%.
What is the most recent average sentiment score for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)?
The most recent average sentiment score for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)?
The most recent sentiment for ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ) is .
SEC-8K** Filing Available For ATARA BIOTHERAPEUTICS INC (ATRA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.